Brian Elsbernd Sells 62,975 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) insider Brian Elsbernd sold 62,975 shares of the business’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the completion of the sale, the insider now owns 188,564 shares in the company, valued at $4,333,200.72. This represents a 25.04 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Catalyst Pharmaceuticals Stock Down 1.0 %

Shares of NASDAQ CPRX traded down $0.21 during midday trading on Wednesday, hitting $21.89. The stock had a trading volume of 993,208 shares, compared to its average volume of 1,271,383. Catalyst Pharmaceuticals, Inc. has a 1-year low of $14.47 and a 1-year high of $24.64. The company has a market capitalization of $2.66 billion, a price-to-earnings ratio of 18.55, a PEG ratio of 3.31 and a beta of 0.80. The company has a fifty day moving average price of $22.27 and a 200 day moving average price of $21.49.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Steward Partners Investment Advisory LLC acquired a new position in shares of Catalyst Pharmaceuticals during the 4th quarter valued at $27,000. Park Square Financial Group LLC acquired a new position in Catalyst Pharmaceuticals during the 4th quarter worth approximately $29,000. Farther Finance Advisors LLC boosted its holdings in Catalyst Pharmaceuticals by 125.1% in the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock worth $56,000 after acquiring an additional 1,495 shares during the period. Larson Financial Group LLC boosted its holdings in Catalyst Pharmaceuticals by 27,218.2% in the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock worth $60,000 after acquiring an additional 2,994 shares during the period. Finally, Wilmington Savings Fund Society FSB acquired a new stake in Catalyst Pharmaceuticals in the fourth quarter valued at approximately $65,000. 79.22% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

CPRX has been the subject of several research reports. Truist Financial lifted their price objective on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, November 11th. Robert W. Baird upped their target price on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an “outperform” rating in a report on Monday. Stephens reaffirmed an “overweight” rating and issued a $33.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. HC Wainwright reissued a “buy” rating and set a $35.00 price target on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Finally, Baird R W raised Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Monday, February 3rd. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, Catalyst Pharmaceuticals currently has an average rating of “Buy” and an average price target of $32.50.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.